RVU120 as a single agent showed clinical benefit in heavily pretreated patients with AML and HR-MDS in the Phase 1 RIVER-51 study (CLI120-001). The strongest evidence of benefit was observed in patients with NPM1 and/or DNMT3A mutations and in patients with HR-MDS. A complete remission (CR) was achieved in a patient with NPM1 and DNMT3A mutations as well as 3 marrow CRs in patients with HR-MDS.
Preclinical results strongly support RVU120 as a candidate for venetoclax relapsed/refractory and frontline AML therapy.
New data in myelofibrosis models show that RVU120 acts synergistically with JAK inhibitors and BET inhibitor – pelabresib. These data support new potential therapeutic options for patients with myelofibrosis. Based on compelling preclinical results, Ryvu plans to launch the clinical study POTAMI-61 (NCT06397313).
